COVID-19: Master Protocols Evaluating Drugs and Biological Products for Treatment or Prevention: Guidance for Industry
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
May 17, 2021
November 7, 2023
44e328fb-a98c-4db7-af9a-8b94f4ea28ea
Related Documents
Adjusting for Covariates in Randomized Clinical Trials for Drugs and Biological Products
Guidance DocumentMay 26, 2023Center for Drug Evaluation and Research
Evaluating Cancer Drugs in Patients with Central Nervous System Metastases: Guidance for Industry
Guidance DocumentJuly 1, 2021Office of the Commissioner
Hematologic Malignancies: Regulatory Considerations for Use of Minimal Residual Disease in Development of Drug and Biological Products for Treatment: Guidance for Industry
Guidance DocumentJanuary 24, 2020Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox